source
- Verdiva Bio halts mid-stage obesity trial of its GLP-1 pill, citing market evolutionVerdiva Bio, a well-funded private biotech, announced it has terminated one of its Phase 2 trials for its lead oral GLP-1 obesity candidate. The company said the decision reflects a shift in the m…
- Soufflé Therapeutics raises $135 million to develop three RNA medicinesSoufflé Therapeutics, a biotech with ties to MIT professor Bob Langer, announced a new financing round. The round raised $135 million from venture capital investors. The capital will be used to a…